课题基金 / 基金详情

The Optimal Anticoagulation for Enhanced Risk Patients Post-Catheter Ablation for Atrial Fibrillation (OCEAN) Trial

The Optimal Anticoagulation for Enhanced Risk Patients Post-Catheter Ablation for Atrial Fibrillation (OCEAN) Trial
房颤导管消融 (OCEAN) 试验后高危患者的最佳抗凝治疗
批准号：
419276
负责人：
Verma Atul
金额：
$69.66万
依托单位：
Ottawa Heart Institute Research Corporation (Ontario)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2020
资助国家：
加拿大
项目状态：
未结题
起止时间：
2020-03-01 至 2025-03-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=419276&lang=en
关键词：
Atrial Fibrillation Catheter Ablation Oral Anticoagulation Randomized Clinical Trial Stroke Prevention

项目摘要

项目成果

Verma Atul的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This trial is comparing medical approaches for stroke prevention in people who have atrial fibrillation (AF) but have undergone a successful procedure called ablation to eliminate or substantially reduce the arrhythmia. AF is normally associated with an i
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The Optimal Anticoagulation for Enhanced Risk Patients Post-Catheter Ablation for Atrial Fibrillation (OCEAN) Trial
海外基金